# High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia

> **NCT01205035** · PHASE2 · COMPLETED · sponsor: **Eye Center of Northern Colorado, P.C.** · enrollment: 6 (actual)

## Conditions studied

- Retinal Diseases
- Telangiectasis

## Interventions

- **DRUG:** ranibizumab 2.0mg

## Key facts

- **NCT ID:** NCT01205035
- **Lead sponsor:** Eye Center of Northern Colorado, P.C.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2015-04-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01205035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01205035, "High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01205035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*